Download Free Breast Cancer Biological And Clinical Progress Book in PDF and EPUB Free Download. You can read online Breast Cancer Biological And Clinical Progress and write the review.

The fight against breast cancer is expected to be effectively stimulated by interdisciplinary approaches and cross-fertilization between laboratory and clinical research findings. Of major importance are therefore meetings promoting fast transfer to clinical applications of findings by basic scientists. The present volume, reporting the proceedings of the 1991 Biennial Conference of the International Association for Breast Cancer Research, hopes to achieve this goal by presenting the most recent observations in the laboratory and their possible applications for diagnostic evaluations and clinical treatments. The sections of the book focus first on the oncogenes more likely involved in mammary tumorigenesis and on the polypeptide factors and steroid hormones affecting proliferation and possibly inducing carcinogenesis in breast epithelium. A section is devoted to the epidemiological studies and to the identification of risk factors, a way to select populations at higher risk and, possibly, to help in preventing the disease. Special emphasis is given to the establishment of diagnostic criteria and to the selection of prognostic factors, which must support an effective therapeutic planning. It is our hope that this volume, a timely update of the most recent advances in specific fields presented by basic scientists, pathologists and clinicians will stimulate new insights and progresses leading ultimately to the control of breast cancer.
Resistance to therapies, both targeted and systemic, and metastases to distant organs are the underlying causes of breast cancer-associated mortality. The second edition of Breast Cancer Metastasis and Drug Resistance brings together some of the leading experts to comprehensively understand breast cancer: the factors that make it lethal, and current research and clinical progress. This volume covers the following core topics: basic understanding of breast cancer (statistics, epidemiology, racial disparity and heterogeneity), metastasis and drug resistance (bone metastasis, trastuzumab resistance, tamoxifen resistance and novel therapeutic targets, including non-coding RNAs, inflammatory cytokines, cancer stem cells, ubiquitin ligases, tumor microenvironment and signaling pathways such as TRAIL, JAK-STAT and mTOR) and recent developments in the field (epigenetic regulation, microRNAs-mediated regulation, novel therapies and the clinically relevant 3D models). Experts also discuss the advances in laboratory research along with their translational and clinical implications with an overarching goal to improve the diagnosis and prognosis, particularly that of breast cancer patients with advanced disease.
Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current knowledge of cancer science and clinical oncology practice. This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients. A translational perspective throughout, integrating cancer biology with cancer management providing an in depth understanding of the disease An emphasis on multidisciplinary, research-driven patient care to improve outcomes and optimal use of all appropriate therapies Cutting-edge coverage of personalized cancer care, including molecular diagnostics and therapeutics Concise, readable, clinically relevant text with algorithms, guidelines and insight into the use of both conventional and novel drugs Includes free access to the Wiley Digital Edition providing search across the book, the full reference list with web links, illustrations and photographs, and post-publication updates
This highly informative book provides a comprehensive, up-to-date and practical reference for daily clinical practice in the management of patients affected by bone metastases. Written by renowned orthopedic surgeons and leading doctors in the respective fields of expertise, it offers a transversal review of the current medical and surgical treatments to allow a real interdisciplinary approach to the oncologic patient according to the highest current standards. The book illustrates all the fundamental medical treatments for metastatic bone diseases and provides an overview of pathology issues related to this condition. An entire section is devoted to main different methods of patients approach. It also provides guidance on all current surgical procedures and minimally invasive treatment techniques. Using a common language and recognizing the different osteoncologic competences, this work allows surgeons, oncologists, radiologists, pathologists and physiatricians to update their expertise and broaden their understanding of how a real team approach can improve the management of these oncology patients.
Each year more than 180,000 new cases of breast cancer are diagnosed in women in the U.S. If cancer is detected when small and local, treatment options are less dangerous, intrusive, and costly-and more likely to lead to a cure. Yet those simple facts belie the complexity of developing and disseminating acceptable techniques for breast cancer diagnosis. Even the most exciting new technologies remain clouded with uncertainty. Mammography and Beyond provides a comprehensive and up-to-date perspective on the state of breast cancer screening and diagnosis and recommends steps for developing the most reliable breast cancer detection methods possible. This book reviews the dramatic expansion of breast cancer awareness and screening, examining the capabilities and limitations of current and emerging technologies for breast cancer detection and their effectiveness at actually reducing deaths. The committee discusses issues including national policy toward breast cancer detection, roles of public and private agencies, problems in determining the success of a technique, availability of detection methods to specific populations of women, women's experience during the detection process, cost-benefit analyses, and more. Examining current practices and specifying research and other needs, Mammography and Beyond will be an indispensable resource to policy makers, public health officials, medical practitioners, researchers, women's health advocates, and concerned women and their families.
In November 1999, the Institute of Medicine, in consultation with the Commission on Life Sciences, the Commission on Physical Sciences, Mathematics, and Applications, and the Board on Science, Technology and Economic Policy launched a one year study on technologies for early detection of breast cancer. The committee was asked to examine technologies under development for early breast cancer detection, and to scrutinize the process of medical technology development, adoption, and dissemination. The committee is gathering information on these topics for its report in a number of ways, including two public workshops that bring in outside expertise. The first workshop on "Developing Technologies for Early Breast Cancer Detection" was held in Washington DC in February 2000. The content of the presentations at the workshop is summarized here. A second workshop, which will focus on the process of technology development and adoption, will be held in Washington, DC on June 19-20. A formal report on these topics, including conclusions and recommendations, will be prepared by the committee upon completion of the one-year study.
Highlighting recent advances in our understanding of breast cancer, this book is intended for a wide audience as a reference book. Included are reviews of genetics, epigenetics, various aspects of cell and molecular biology, and several other areas of breast cancer that are aimed at determining new intervention sites for treatments and cures of the disease. The chapters are written by internationally recognized experts and include reviews of key topics in breast cancer research. Each chapter highlights the new aspects of specific research topics and the various impacts of designing new strategies as well as identifies new targets for therapeutic intervention. The topics addressed are selected to be of interest to patients, scientists, students, teachers, and anyone else interested in expanding their knowledge of breast cancer imaging, diagnostics, therapeutics, or basic biomedical research on breast cancer.
This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient’s genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors provide an in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.
An ideal health care system relies on efficiently generating timely, accurate evidence to deliver on its promise of diminishing the divide between clinical practice and research. There are growing indications, however, that the current health care system and the clinical research that guides medical decisions in the United States falls far short of this vision. The process of generating medical evidence through clinical trials in the United States is expensive and lengthy, includes a number of regulatory hurdles, and is based on a limited infrastructure. The link between clinical research and medical progress is also frequently misunderstood or unsupported by both patients and providers. The focus of clinical research changes as diseases emerge and new treatments create cures for old conditions. As diseases evolve, the ultimate goal remains to speed new and improved medical treatments to patients throughout the world. To keep pace with rapidly changing health care demands, clinical research resources need to be organized and on hand to address the numerous health care questions that continually emerge. Improving the overall capacity of the clinical research enterprise will depend on ensuring that there is an adequate infrastructure in place to support the investigators who conduct research, the patients with real diseases who volunteer to participate in experimental research, and the institutions that organize and carry out the trials. To address these issues and better understand the current state of clinical research in the United States, the Institute of Medicine's (IOM) Forum on Drug Discovery, Development, and Translation held a 2-day workshop entitled Transforming Clinical Research in the United States. The workshop, summarized in this volume, laid the foundation for a broader initiative of the Forum addressing different aspects of clinical research. Future Forum plans include further examining regulatory, administrative, and structural barriers to the effective conduct of clinical research; developing a vision for a stable, continuously funded clinical research infrastructure in the United States; and considering strategies and collaborative activities to facilitate more robust public engagement in the clinical research enterprise.